MEDVi vs ShedRx: November 2026 prices compared
As of November 20, 2026, neither MEDVi nor ShedRx printed a month-to-month compounded price that applies at the maintenance dose, so this page compares what each did show and how each bills, without a price verdict.
Released · Last reviewed · how we verify
MEDVi and ShedRx, measure by measure
| Measure | MEDVi | ShedRx |
|---|---|---|
| Tirzepatide, month to month | — | from $239 (lowest printed: "starting as low as"; no month-to-month figure) |
| Tirzepatide, lowest printed | — | $239 ("starting as low as") |
| Semaglutide, month to month | — | from $159 (lowest printed: "GLP-1s from $159/mo" (drug not named); no month-to-month figure) |
| Semaglutide, lowest printed | — | $159 ("GLP-1s from $159/mo" (drug not named)) |
| Dose pricing | not confirmed | priced by dose or not stated |
| Membership or program fee | not confirmed | none |
| Computed score | 0 of 40 (position 21 of 27) | 12 of 40 (position 16 of 27) |
| FDA warning letters | 721455 (2026-02-20) | none listed |
| November 20 read | not readable Nov 20 | first-party read |
Strengths and limitations: which fits whom
MEDVi cannot be judged on price this month because its page could not be read on November 20, 2026. ShedRx prints a month-to-month price; confirm whether it changes with the dose before you rely on it for a year. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| ShedRx | tirzepatide | — | from $239 |
| ShedRx | semaglutide | — | from $159 |
Regulatory record
FDA’s warning-letter index lists warning letter 721455 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to MEDVi; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, MEDVi or ShedRx?
Neither printed a comparable month-to-month price on November 20, 2026, so there is no like-for-like answer this month.
Do MEDVi and ShedRx charge a membership fee?
MEDVi: not confirmed on November 20, 2026; ShedRx: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are MEDVi and ShedRx medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- MEDVi pricing page (not readable on November 20, 2026)
- ShedRx pricing page (read November 20, 2026)
- FDA warning letter 721455 to MEDVi (dated 2026-02-20, posted 2026-03-03)